Skip to content

US · OLMA · BIOTECHNOLOGY

Olema Pharmaceuticals, Inc. (OLMA) intrinsic value and stock valuation

$7.02as of 2026-11-21 · Mkt cap 1.05B

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Olema Pharmaceuticals, Inc. DCF and intrinsic value

InvestorsCraft values OLMA with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from OLMA’s statements →

Olema Pharmaceuticals, Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology San Francisco, CA 94103 olema.com

How the business is doing

Fiscal 2018–2025, USD

Revenue
$0.00
20182025
Net income
-$-162.45M
20182025
Free cash flow
-$-146.72M
20182025
Total equity
$478.6M+7.2% 5y CAGRd
20182025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2018–2025, USD
20252024202320222021
Revenue$0.00$0.00$0.00$0.00$0.00
Operating income-$-178.7M-$-142.26M-$-104.96M-$-106.99M-$-71.49M
Net income-$-162.45M-$-129.47M-$-96.66M-$-104.79M-$-71.1M
EPSd-$-1.87M-$-2.2M-$-2.14M-$-2.62M-$-1.8M
Operating cash flow-$-146.72M-$-104.35M-$-83.73M-$-82.06M-$-50.69M
Capital expenditure$0.00-$-160K$0.00-$-360K-$-1.57M
Free cash flow-$-146.72M-$-104.51M-$-83.73M-$-82.43M-$-52.27M
Total assets$533.4M$451M$276.9M$215.7M$295.9M
Total debt$1.19M$1.43M$2.42M$2.56M$3.29M
Net debt-$-47.11M-$-138.05M-$-66.12M-$-21.14M-$-10.52M
Total equity$478.6M$409M$253.9M$197.6M$284.6M
Cash and short-term investments$505.4M$434.1M$261.8M$204.4M$287.3M
Income statement
20252024202320222021
Revenue$0.00$0.00$0.00$0.00$0.00
Cost of revenue$0.00$0.00$0.00$0.00$0.00
Gross profit$0.00$0.00$0.00$0.00$0.00
Research and development expenses$157.7M$124.5M$86.1M$82.3M$51.1M
Selling, general and administrative expenses$21M$17.7M$18.8M$24.7M$20.4M
Other expenses$0.00$0.00$0.00$0.00$0.00
Operating expenses$178.7M$142.3M$105M$107M$71.5M
Cost and expenses$178.7M$142.3M$105M$107M$71.5M
Interest income$16.2M$12.7M$8.32M$2.23M$440K
Interest expense$0.00$0.00$0.00$0.00$0.00
Depreciation and amortization$490K$390K$380K$360K$160K
Ebitda-$-161.96M-$-129.08M-$-96.28M-$-104.43M-$-70.93M
Operating income-$-178.7M-$-142.26M-$-104.96M-$-106.99M-$-71.49M
Total other income/expenses, net$16.3M$12.8M$8.31M$2.2M$400K
Income before tax-$-162.45M-$-129.47M-$-96.66M-$-104.79M-$-71.1M
Income tax expense$0.00$0.00$0.00$0.00$0.00
Net income-$-162.45M-$-129.47M-$-96.66M-$-104.79M-$-71.1M
Weighted average shares outstanding$87M$58.7M$45.3M$40M$39.5M
Weighted average diluted shares outstanding$87M$58.7M$45.3M$40M$39.5M
Balance sheet
20252024202320222021
Cash and short-term investments$505.4M$434.1M$261.8M$204.4M$287.3M
Net receivables$4.06M$2.12M$670K$320K$130K
Inventory$0.00$0.00$0.00$0.00$0.00
Total current assets$515.5M$438.5M$266.5M$208.9M$290.7M
Property, plant and equipment, net$1.15M$2.06M$3.26M$3.98M$4.72M
Goodwill and intangible assets$0.00$680K$0.00$0.00$0.00
Long-term investments$0.00$0.00$0.00$0.00$0.00
Total non-current assets$18M$12.5M$10.4M$6.75M$5.26M
Total assets$533.4M$451M$276.9M$215.7M$295.9M
Accounts payable$9.25M$4.46M$2.7M$370K$20K
Short-term debt$1.12M$1.17M$990K$1.01M$930K
Deferred revenue$0.00$0.00$0.00$0.00$0.00
Total current liabilities$51.8M$41.8M$21.6M$16.6M$9.02M
Long-term debt$70K$260K$1.43M$1.55M$2.36M
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$3.07M$260K$1.43M$1.55M$2.36M
Capital lease obligations$0.00$260K$2.42M$2.56M$3.29M
Total liabilities$54.9M$42M$23.1M$18.1M$11.4M
Common stock$10K$10K$0.00$0.00$0.00
Retained earnings-$-597.56M-$-435.11M-$-305.63M-$-208.98M-$-104.19M
Accumulated other comprehensive income (loss)$620K$140K$350K-$-1.81M-$-150K
Total equity$478.6M$409M$253.9M$197.6M$284.6M
Total investments$457.1M$294.6M$193.3M$180.7M$273.4M
Total debt$1.19M$1.43M$2.42M$2.56M$3.29M
Net debt-$-47.11M-$-138.05M-$-66.12M-$-21.14M-$-10.52M
Cash flow statement
20252024202320222021
Net income-$-162.45M-$-129.47M-$-96.66M-$-104.79M-$-71.1M
Depreciation and amortization$490K$390K$380K$1.66M$1.66M
Stock-based compensation$17.6M$22.6M$17.3M$0.00$0.00
Change in working capital$2.77M$9.16M-$-590K$3.02M$2.83M
Accounts receivable$0.00$0.00$0.00$0.00$0.00
Inventory$0.00$0.00$0.00$0.00$0.00
Accounts payable$4.6M$2.51M$2.32M$350K-$-680K
Net cash provided by operating activities-$-146.72M-$-104.35M-$-83.73M-$-82.06M-$-50.69M
Investments in property, plant and equipment$0.00-$-160K$0.00-$-360K-$-1.57M
Acquisitions, net$0.00$0.00$0.00$0.00$0.00
Net cash used for investing activities-$-155.76M-$-93.53M-$-4.85M$91.5M-$-275.44M
Common stock issued$208.3M$266.3M$129.7M$480K$1.39M
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$211.3M$268.8M$133.4M$480K$1.39M
Net change in cash-$-91.18M$70.9M$44.8M$9.89M-$-324.74M
Cash at end of period$48.3M$139.5M$68.5M$23.7M$13.8M
Operating cash flow-$-146.72M-$-104.35M-$-83.73M-$-82.06M-$-50.69M
Capital expenditure$0.00-$-160K$0.00-$-360K-$-1.57M
Free cash flow-$-146.72M-$-104.51M-$-83.73M-$-82.43M-$-52.27M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Olema Pharmaceuticals, Inc.

        Olema Pharmaceuticals, Inc., a biopharmaceutical enterprise in the clinical development stage, is dedicated to discovering, advancing, and commercializing therapeutic solutions for women's oncology. Headquartered in San Francisco, California, the company was established in 2006 and rebranded from CombiThera, Inc. in March 2009. Its most promising investigational compound, OP-1250, an estrogen receptor (ER) antagonist and selective ER degrader, is presently undergoing Phase 1/2 clinical evaluations. This drug candidate is being assessed for its efficacy in managing recurrent, locally advanced, or metastatic breast cancer that expresses estrogen receptors but is negative for human epidermal growth factor receptor 2.

        CEO
        Sean Bohen
        Employees
        131
        Beta
        2.01

        Explore

        Frequently asked questions

        What is the intrinsic value of Olema Pharmaceuticals, Inc. (OLMA)?

        InvestorsCraft does not currently publish an intrinsic value for OLMA. How the IC value is calculated.

        Is OLMA undervalued?

        InvestorsCraft does not publish an undervaluation signal for OLMA at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.